What does this study add?
• Ixekizumab significantly improved the severity of genital psoriasis and associated disease characteristics.
• Ixekizumab may be appropriate for treatment of moderate-to-severe genital psoriasis, even in patients with limited body surface involvement.
Up to 63% of patients with psoriasis experience genital skin involvement at some point during the course of their disease. 1 Genital psoriasis (GenPs) is a particularly challenging manifestation of psoriasis with significantly greater negative impacts on sexual health and quality of life than in patients with psoriasis with no genital involvement. [1] [2] [3] Nevertheless, GenPs often remains undiagnosed due to insufficient evaluation of patients for genital involvement and a reluctance of patients and healthcare providers to discuss GenPs. 4 The sensitive genital skin limits treatment options because many standard topical or ultraviolet-based treatments for psoriasis are either contraindicated or not well tolerated on genital skin. Current treatment guidelines support systemic therapies for GenPs when other treatment options fail, even in patients with lower body surface area (BSA) involvement. 5 However, interventional clinical studies for GenPs are sparse. [6] [7] [8] [9] Therefore, there is an unmet clinical need for effective therapies for GenPs when topical therapies are ineffective or not well tolerated.
Ixekizumab results in rapid achievement of high clinical response rates that persist over long-term treatment of patients with moderate-to-severe plaque psoriasis. [10] [11] [12] However, the efficacy of ixekizumab for GenPs is unknown. We report the efficacy and safety results from the 12-week blinded treatment period of a randomized, double-blinded, phase IIIb clinical trial investigating the impact of ixekizumab on GenPs severity, sexual health and health-related quality of life (HRQoL) in patients with ≥ 1% involved BSA and moderate-to-severe GenPs, as defined by a baseline score of 3 (moderate) or more on the static Physician's Global Assessment of Genitalia (sPGA-G). The primary outcome measure (sPGA-G) was developed for assessment of the severity of GenPs and was validated using data from the screening and baseline visits of IXORA-Q. Herein we provide results for the assessment of the psychometric properties of the sPGA-G (Appendix S1, Tables S1 and S2; see Supporting Information). A description of the conceptualization, development methodology and content validity of the sPGA-G has been published previously. 13 
Patients and methods

Participants
Participants were ≥ 18 years old; had chronic plaque psoriasis for ≥ 6 months prior to baseline; had moderate-to-severe genital (sPGA-G ≥ 3) and overall psoriasis (overall sPGA ≥ 3); had plaque psoriasis in a nongenital area; had BSA involvement of ≥ 1% (up to 40% of enrolled patients could have BSA < 10%); were candidates for phototherapy or systemic therapy; had previously failed to respond to, or were intolerant of, at least one topical therapy for GenPs; and had agreed to use a reliable method of birth control.
Patients were excluded if they had forms of psoriasis other than plaque psoriasis, had pustules or vesicles in the genital area, or had previously received treatment with interleukin-17 antagonists. Additional key exclusion criteria included prior exposure to agents targeting a-4 integrin, live vaccination within 12 weeks prior to baseline, current or prior history of lymphoproliferative disease or malignant disease within 5 years prior to baseline, a recent history of suicide attempt (≤ 30 days) or a score of 3 on item 12 (thoughts of death or suicide) on the Quick Inventory of Depressive Symptomatology Self-Report (16 items) at screening or baseline or a history of histoplasmosis, coccidioidomycosis or any other infection typical of an immunocompromised host. Complete inclusion and exclusion criteria are available in Appendix S1 (see Supporting Information).
Study design
Participants were randomized 1 : 1 to ixekizumab (160 mg at week 0, then 80 mg every 2 weeks through week 12) or placebo during a 12-week blinded treatment period. Participants then entered a currently ongoing open-label treatment period through week 52.
IXORA-Q (Clinicaltrials.gov listing NCT02718898) was conducted in accordance with the ethical principles of the Declaration of Helsinki. All patients provided written informed consent before undergoing study-related procedures.
Outcomes
Efficacy
The primary end point was to determine whether ixekizumab was superior to placebo at week 12 as determined by the percentage of patients achieving 0 or 1 (clear or minimal) on the sPGA-G. 13 The major secondary end points were to determine whether ixekizumab was superior to placebo at week 12 as determined by the percentage of patients achieving 0 or 1 (clear or minimal) on the overall sPGA, a clinically meaningful (≥ 3-point) improvement from baseline for patients with ≥ 3 at baseline on the GenPs itch numerical rating scale (NRS), and a GenPs Sexual Frequency Questionnaire (GenPs-SFQ) 15 item 2 score of 0 or 1 for patients with a score ≥ 2 at baseline. Additional secondary end points included mean change from baseline in the modified GenPs Area and Severity Index (mGPASI) 1, 9 and in the Dermatology Life Quality Index (DLQI) at week 12. The percentage of patients achieving 0 or 1 on the DLQI at week 12 was also measured. The GenPs-SFQ 15 is a two-item, patient-reported outcome measure to assess the impact of GenPs on the frequency of sexual activity (including nonintercourse activities such as masturbation). Item 1 assesses the overall frequency of sexual activity by asking how often in the last week patients engaged in sexual activity (none/zero, once, or two or more times). Item 2 assesses the impact of GenPs on the frequency of sexual activity by asking how often during the last week GenPs symptoms limited the frequency of sexual activity; responses include never (0), rarely (1), sometimes (2), often (3) or always (4) . Additional details on outcome measures are described in Appendix S1 (see Supporting Information).
Investigators were trained in the use of the sPGA-G for clinical assessment of GenPs through either an in-person or online training module, which was accompanied by a certification examination. Details on the training module and examination are described in Merola et al. 13 The GenPs-SFQ item 2 and genital itch NRS were collected using an electronic diary that included instructions and guidance for self-assessment.
Safety
Safety was evaluated by monitoring of adverse events (AEs) for all enrolled patients. Treatment-emergent AEs (TEAEs) were defined as any unfavourable or unintended sign (including laboratory results), symptom or disease that first occurred or worsened on or after baseline. TEAEs were classified by severity, relationship with study drug or procedure, and association with patient discontinuation. AEs of special interest included cytopenias, liver function test changes or enzyme elevations, infections, injection-site reactions, allergic reactions or hypersensitivities, cerebrocardiovascular events, malignancies, inflammatory bowel disease and depression.
Statistical analysis
Sample-size determination
Study enrolment was planned for approximately 146 patients randomized 1 : 1 into treatment groups. As no biological drug had been evaluated in a large-scale, randomized, phase III clinical trial and no prior data existed for the sPGA-G, the sample size was calculated based on data from the assessment of DLQI item 9 (sexual difficulties due to skin) from phase II and phase III studies of ixekizumab in plaque psoriasis. Assumptions based on data from these studies included rates of 2% and 20% for skin-related sexual difficulties for the ixekizumab and placebo treatment groups, respectively. Power calculations used a two-sided Fisher's exact test at a 0Á05 level of significance. With 146 patients (73 per treatment group) the study was calculated to have 94% power.
Efficacy and safety analysis
Efficacy analyses were performed for all randomized patients according to the treatment group to which they were 
46 (62) 44 (59) Unless otherwise indicated, all values are presented as the mean AE SD. DLQI, Dermatology Life Quality Index; GenPs-SFQ, Genital Psoriasis Sexual Frequency Questionnaire; mGPASI, modified Genital Psoriasis Area and Severity Index; sPGA, static Physician's Global Assessment; sPGA-G, sPGA of Genitalia. a The ixekizumab treatment group included one transgender patient in the male population who identified as female but had male genitalia. b One patient in the ixekizumab treatment group was inadvertently enrolled with a baseline sPGA-G of 1. Therefore, this patient was not included in the count of patients with an sPGA-G score of 3, 4 or 5 in the ixekizumab group or the total study population.
assigned (intent-to-treat population). A gatekeeping strategy for testing the primary and major secondary end points was implemented to control the overall type I error rate at a two-sided alpha level of 0Á05 (details are described in Appendix S1; see Supporting Information). There was no adjustment for multiple comparisons for any other secondary end points or time points. Categorical efficacy and health outcome variables were analysed using a logistic regression model accounting for missing data using nonresponder imputation, in which patients were defined as nonresponders if they did not meet the clinical response criteria or had missing clinical response data for any reason including discontinuation at the analysis time point, unless otherwise specified. Continuous variables were analysed using a mixed-effects model for repeated measures (MMRM). Type III tests for the least square mean (LSM) were used for statistical comparisons between treatment groups for continuous variables. Both the logistic and MMRM models included baseline BSA category (1 to < 10% vs. ≥ 10%) as a covariate. Subgroup analysis for sPGA-G 0/1 response at week 12 using nonresponder imputation within each BSA subgroup (baseline BSA of 1 to < 10% or ≥ 10%) and sex (male or female) was performed.
Safety outcomes were summarized for all randomized patients who received at least one dose of investigational product according to the treatment group to which they were assigned. Safety data were summarized as the frequency of events in each treatment group.
Additional details of the statistical methods are described in Appendix S1.
Results
Patients
Patients (n = 149) were randomized from 5 May 2016 to 1 December 2016 to receive placebo (n = 74) or ixekizumab 80 mg every 2 weeks (n = 75) during the 12-week blinded treatment period. Overall, 99% (n = 74) of patients randomized to ixekizumab and 88% (n = 65) of those randomized to placebo completed the blinded treatment period ( Fig. S1 ; see Supporting Information).
The baseline demographics and disease characteristics were similar between the placebo and ixekizumab treatment groups (Table 1 ). Overall, 75Á8% of patients were male (the ixekizumab treatment group included one transgender patient in the male population who identified as female but had male genitalia). The mean AE SD age was 43Á7 AE 12Á7 years (range 19-77), the mean weight was 93Á5 AE 24Á7 kg and 39Á6% of patients had 1% to < 10% BSA involvement. Previous systemic therapies were used by 52Á3% (nonbiologics) and 19Á5% (biologics) of patients. The inclusion criteria required all patients to have previously used topical therapies; 35Á6% had previously used at least two topical therapies and 83Á9% of patients had discontinued previous topical therapy for GenPs because of either inadequate response or loss of response.
Efficacy
The primary and all major secondary end points were met. At week 12, significantly more patients achieved clear or almost clear genital skin (sPGA-G 0/1) with ixekizumab (73%) vs. placebo (8%, P < 0Á001). Completely clear genital skin (sPGA-G 0) was achieved in significantly more patients receiving ixekizumab (56%) than placebo (5%, P < 0Á001) (Fig 1a) . The mixedeffects model for repeated measures includes treatment, baseline BSA category, baseline value, visit, treatment-by-visit interaction and baseline value-by-visit interactions as fixed factors, with variancecovariance structure set to unstructured. IXE vs. placebo (PBO): *P < 0Á05, **P < 0Á01; ***P < 0Á001. A multiple testing strategy was used for statistical analysis of the primary end point and major secondary end points; P-values for other time points and outcome measures were not adjusted for multiple comparisons. Error bars indicate 95% confidence intervals (a, b) or standard error (c).
(ixekizumab 24%, placebo 1%; P = 0Á003) and sPGA-G 0 (ixekizumab 8%, placebo 0%, P = 0Á028). At week 12, response rates for sPGA-G 0/1 were consistent across lower (1 to < 10%) and higher (≥ 10%) BSA subgroups with ixekizumab (BSA 1 to < 10%, 71%; BSA ≥ 10%, 75%), and were significantly greater than with placebo (both P < 0Á001) (Fig. 1b) . Similarly, week 12 sPGA-G 0/1 response rates were consistent between male and female patients, and response was significantly greater (P < 0Á001) with ixekizumab (male 71%, female 79%) than with placebo (male 9%, female 6%). The LSM AE SE change from baseline in the mGPASI was significantly greater with ixekizumab at week 12 (ixekizumab À23Á9 AE 1Á48, placebo À3Á9 AE 1Á56; P < 0Á001) (Fig. 1c) . Figure 2 illustrates the clearance of GenPs for a patient randomized to ixekizumab. Ixekizumab resulted in significantly greater improvement in overall plaque psoriasis at week 12 vs. placebo for both overall sPGA 0/1 (ixekizumab 73%, placebo 3%; P < 0Á001) and overall sPGA 0 (ixekizumab 40%, placebo 0%; P < 0Á001) (Fig. 3a) . Statistically significant improvements were observed with ixekizumab as early as weeks 1 and 4 for overall sPGA 0/1 (ixekizumab 17%, placebo 0%; P < 0Á001) and overall sPGA 0 (ixekizumab 16%, placebo 0%; P < 0Á001).
Significantly more patients achieved a clinically meaningful (≥ 3-point) improvement (reduction) from baseline in the genital itch NRS with ixekizumab (60%) vs. placebo (8%, P < 0Á001) at week 12 among patients with a baseline score ≥ 3 (ixekizumab, n = 62; placebo, n = 60) (Fig. 3b) . Statistically significant differences in genital itch were observed as early as week 2 (ixekizumab 34%, placebo 5%; P < 0Á001). Definitions of response in the itch NRS are provided in Appendix S1 and Tables S3-S5 (see Supporting Information) .
Among patients with a GenPs-SFQ item 2 score of ≥ 2 at baseline (ixekizumab, n = 37; placebo, n = 42), significantly more patients treated with ixekizumab achieved GenPs-SFQ item 2 score 0/1 (indicating GenPs never or rarely limited sexual activity) at week 12 (ixekizumab 78%, placebo 21%; P < 0Á001) (Fig. 3c ). Significant improvement with ixekizumab was observed as early as week 1 (ixekizumab 22%, placebo 5%; P = 0Á036).
At week 12, HRQoL significantly improved with ixekizumab as determined by LSM change from baseline in DLQI (ixekizumab À9Á7 AE 0Á59, placebo À1Á4 AE 0Á62; P < 0Á001) and DLQI 0/1 response rate (ixekizumab 45%, placebo 3%; P < 0Á001) ( Table 2) . A score of 0 or 1 on the DLQI indicates no effect on HRQoL.
Safety
Safety outcomes during the blinded treatment period are summarized in Table 3 . TEAEs were more frequent with ixekizumab than with placebo, but were not significantly different between treatment groups (P = 0Á19). Most TEAEs were mild or moderate in severity, with three (4%) severe TEAEs in the placebo group vs. one (1%) with ixekizumab. The most common TEAEs (those occurring at a frequency of ≥ 2% in the ixekizumab group and with greater frequency in patients receiving ixekizumab than placebo) were upper respiratory tract infection, injection-site reactions, oropharyngeal pain, pruritus, back pain, eczema and hypertension. Five (7%) patients receiving placebo and one (1%) receiving ixekizumab discontinued due to an AE. One serious AE (acute pancreatitis) occurred in a patient receiving placebo and resolved without discontinuation, and there were no deaths.
Injection-site reactions were mild or moderate in severity and occurred more frequently in the ixekizumab treatment group (11%) than in the placebo group (3%). None of the injection-site reactions resulted in study discontinuation.
Treatment-emergent (TE) infections were more frequent with ixekizumab (24%) than with placebo (18%). Allergic or hypersensitivity reactions occurred at similar rates in the placebo (4%) and ixekizumab (5%) treatment groups. No cases of candidiasis or anaphylaxis were reported, there were no infection-related discontinuations and one patient discontinued due to allergic or hypersensitivity reactions. All TE infections and allergic or hypersensitivity reactions were mild or moderate in severity, except for one patient receiving ixekizumab who experienced two separate severe events during the blinded treatment period, reported by the investigator as a TE infection (infected eczema on the right thigh and right antecubital fossa) and an allergic or hypersensitivity reaction (exacerbation of eczema, resulting in study discontinuation). Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) item 2 score of 0 or 1 (of patients with a baseline score ≥ 2). IXE vs. placebo (PBO): *P < 0Á05, **P < 0Á01; ***P < 0Á001. A multiple testing strategy was used for statistical analysis of the primary end point and major secondary end points; P-values for other time points and measures were not adjusted for multiple comparisons. Error bars indicate 95% confidence intervals. The sites of eczema were distant from the injection sites (abdomen) and this patient did not experience any injection-site reactions. TE depression was reported in two patients (3%) in the placebo group, with no resultant discontinuation from the study. At baseline, 11 patients reported a prior history of suicidal ideation or behaviour (ixekizumab, three patients; placebo, eight patients), none of whom reported suicidal ideation or behaviour at any point during the blinded treatment period. Two patients (both receiving placebo) with no history of suicidal ideation or behaviour reported experiencing suicidal ideation or behaviour during the blinded treatment period.
Two patients (3%) in the placebo group developed hepaticrelated TEAEs, one of whom discontinued due to an increased liver function test. There were no TE cytopenias, cerebrocardiovascular events, inflammatory bowel disease or malignancies reported during the blinded treatment period.
Discussion
Ixekizumab was superior to placebo for the treatment of moderate-to-severe GenPs during 12 weeks of treatment. Most (73%) patients receiving ixekizumab achieved complete or nearly complete resolution and 56% achieved complete resolution of GenPs. Consistently with previous clinical studies of ixekizumab, 73% of patients achieved overall sPGA 0/1, and 40% achieved overall sPGA 0 at week 12.
10 Clinical response was rapid, with significant improvement as early as week 1 for sPGA-G 0/1, sPGA-G 0 and overall sPGA 0/1, and as early as week 4 for overall sPGA 0. Ixekizumab resulted in clinically meaningful improvements in genital itch and HRQoL, and significantly reduced the negative impact of GenPs on the frequency of sexual activity at week 12. Nearly 60% of patients receiving ixekizumab (with a baseline genital itch NRS ≥ 3) displayed a clinically meaningful improvement at week 12, with significant improvement as early as week 2. Among patients who reported an impact on sexual frequency at baseline due to GenPs (GenPs-SFQ item 2 score ≥ 2), nearly 80% receiving ixekizumab improved to the point that their frequency of sexual activity was never or rarely limited by GenPs at week 12, with significant improvement observed as early as week 1. HRQoL also significantly improved with ixekizumab, with 45% of patients receiving ixekizumab reporting no clinically significant impact on HRQoL at week 12.
The overall safety profile of ixekizumab in this study was comparable with those reported in previous studies of ixekizumab in moderate-to-severe plaque psoriasis. 10 Most TEAEs were mild or moderate in severity and discontinuations due to AEs were rare (one ixekizumab-treated patient). During the blinded treatment period, only one serious AE was reported, in a patient receiving placebo, and no deaths occurred. The study population was globally diverse, with 149 patients enrolled from 34 sites in seven countries. This study is the only phase III, randomized, placebo-controlled, doubleblinded clinical trial that has evaluated the efficacy of any therapy for the treatment of GenPs. Patients with both lower (1% to < 10%) and higher (≥ 10%) BSA involvement were included in this study. Thus, this study is among a small number of clinical trials investigating systemic therapy for plaque psoriasis in patients with < 10% BSA involvement where the severity and impact of the disease is considerable. A limitation of this study is that it did not include an active comparator, in part due to a lack of any well-established treatments for moderate-to-severe GenPs. Additionally, the study population was predominantly white and male. Lastly, this study had a relatively short duration. However, continued monitoring of the efficacy and safety of ixekizumab for GenPs is currently ongoing during an open-label extension period.
Although GenPs is a common and burdensome manifestation of plaque psoriasis, [1] [2] [3] there are few published open-label studies that have evaluated the efficacy of interventional treatments for GenPs. [7] [8] [9] 16 In this study, ixekizumab provided rapid and significant improvement in GenPs that was consistent across lower and higher BSA subgroups. Ixekizumab also provided rapid and significant improvement in the impact of GenPs on the frequency of sexual activity and in HRQoL.
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